Troncone L, Rufini V, Daidone M S, De Santis M, Luzi S
Department of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):295-9.
Five cases of malignant pheochromocytoma (3 men and 2 women, aged 26-43 years) were treated with [131I]metaiodobenzylguanidine (131I-MIBG). One patient had a voluminous adrenal tumor and multiple distant metastases; two patients had a recurrent tumor; two others a post-surgical residual tumor. The therapeutic procedure essentially consisted of single doses (2.6-7.4 GBq) of 131I-MIBG administered by slow i.v. infusion, given in several therapeutic courses at 1-5 month intervals. The treatment resulted in a complete response in one case with residual tumor and in a partial response in the case with disseminated disease. Two cases showed stabilization of the disease, whereas therapy was ineffective in the fifth case. Nevertheless, pain relief was observed in this patient. The treatment had a very low toxicity and was well tolerated by all patients.
5例恶性嗜铬细胞瘤患者（3例男性，2例女性，年龄26 - 43岁）接受了[131I]间碘苄胍（131I - MIBG）治疗。1例患者有巨大肾上腺肿瘤并伴有多处远处转移；2例患者为复发性肿瘤；另外2例为术后残留肿瘤。治疗过程主要包括通过静脉缓慢输注给予单剂量（2.6 - 7.4 GBq）的131I - MIBG，在1 - 5个月的间隔内进行多个疗程治疗。治疗使1例残留肿瘤患者完全缓解，1例播散性疾病患者部分缓解。2例患者病情稳定，而第5例患者治疗无效。不过，该患者疼痛得到缓解。治疗毒性非常低，所有患者耐受性良好。
